News
8
blog,bridge-core-1.0.4,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-18.0.8,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-5.7,vc_responsive

Vaccibody calls for Annual General Meeting to be held on May 13, 2019 at 10.00 AM in Forskningsparken, Oslo. Shareholders will receive the call documents electronically or by post. The call documents can also be downloaded here. ...

Oslo/San Francisco, April 1, 2019 – Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced presentation of new preclinical data for VB10.NEO, a personalized neoantigen cancer vaccine, combined with bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist. These data were presented today in a...

Oslo, March 25, 2019 Vaccibody AS today announced positive 12-month results from the phase IIa part of the clinical study VB C-01. This study is a first human dose, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial...

  Poster presentations of Vaccibody’s two lead candidates: 6M interim clinical data on VB10.16, and preclinical data on VB10.NEO alone and in combination with bempegaldesleukin (NKTR-214)    Oslo, Norway, February 27th, 2019 – Vaccibody AS today announced that clinical and preclinical data will be presented at the upcoming 2019...

Vaccibody AS, a clinical stage immuno-oncology company, announced today that it has entered into a collaboration with Roche to explore a combination of Vaccibody’s VB10.16 and the PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced cervical cancer. Vaccibody expects to start a phase II...